Dr BG Rhee, CEO of SCM Lifescience discusses their patented proprietary subfraction technology to extract high purity cell cultures, and the impact this will have on the efficacy, cell differentiation ability, and cost of stem cell treatments. Dr Rhee also provides his assessment of the regulatory framework for stem cells in Korea, and some of the challenges the smaller companies are encountering when looking to globalize.
The difference between SCM and other stem cell companies is that we have the highest purity stem cells thanks to our different manufacturing scheme
